Combined Antiplatelet and Anticoagulant Therapy

Introduction to Combined Therapy

The European Society of Cardiology recommends the lowest prescribed dose combination of clopidogrel 75 mg daily plus apixaban 2.5 mg twice daily for patients requiring dual therapy with an oral anticoagulant who meet dose-reduction criteria 1, 2

The American College of Cardiology suggests that clopidogrel 75 mg once daily is the established maintenance dose across all guidelines for patients requiring antiplatelet therapy 1, 2, 3
The European Heart Society indicates that apixaban 2.5 mg twice daily is the reduced dose approved for stroke prevention in atrial fibrillation when patients meet at least 2 of the following criteria: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL 1, 2, 4

When a NOAC (like apixaban) is used in combination with clopidogrel, the lowest approved dose effective for stroke prevention tested in AF trials should be considered 1, 2
For patients with atrial fibrillation undergoing PCI or with acute coronary syndrome, dual therapy with clopidogrel 75 mg/day and oral anticoagulation should be considered as an alternative to triple antithrombotic therapy in patients where bleeding risk outweighs ischemic risk 1, 2

If patient meets ≥2 criteria (age ≥80 years, weight ≤60 kg, creatinine ≥1.5 mg/dL): Use apixaban 2.5 mg twice daily 1, 2, 4
Maintenance dose of clopidogrel is always 75 mg once daily regardless of patient characteristics 1, 2, 3

The combination of clopidogrel and apixaban significantly increases bleeding risk compared to monotherapy 1, 2
Patients receiving dual therapy should have time in therapeutic range monitored if transitioning from warfarin, with target INR 2.0-2.5 when triple therapy is necessary 1, 6

Discontinuation of antiplatelet treatment in patients treated with oral anticoagulation should be considered at 12 months 1, 2
Beyond 12 months, oral anticoagulation alone is superior to combination therapy for most patients, as the bleeding risk outweighs additional thrombotic protection 1, 2

Do not use prasugrel or ticagrelor instead of clopidogrel when combining with oral anticoagulation, as these agents are not recommended as part of triple antithrombotic therapy 1, 2
Do not continue triple therapy beyond 1 month unless very high ischemic risk features are present, as bleeding risk peaks within the first 30 days 1, 2
Do not use rivaroxaban 20 mg daily when combining with antiplatelet therapy; the reduced dose of 15 mg daily should be considered instead 1, 2